3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
3
Smoking
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Hyperlipoproteinemia Type II
1
Hematologic Neoplasms
1
Diabetes Mellitus
1
Dementia
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
COVID-19
1
Interventions
Rituximab
25
Lenalidomide
20
Cyclophosphamide
18
obinutuzumab
8
Vincristine
8
Doxorubicin
8
Prednisone
7
Bendamustine Hydrochloride
7
tazemetostat
6
ibrutinib
6
Biopsy
6
venetoclax
5
pembrolizumab
5
fludarabine
5
Specimen Handling
5
CT-P10
5
fludarabine phosphate
4
R-CHOP protocol
4
Peripheral Blood Stem Cell Transplantation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Prednisolone
3
Etoposide
3
tocilizumab
2
copanlisib
2
axicabtagene ciloleucel
2
atezolizumab
2
acalabrutinib
2
abexinostat
2
Whole-Body Irradiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Follicular
×
Atorvastatin
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled